Role of <sup>64</sup>CuCl<sub>2</sub> PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and <sup>18</sup>F-FDG PET/CT.
Where this comes from
- Record sourced from PubMed, PMID 39054284.
- Also identified by DOI 10.2967/jnumed.124.267474.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Molecular imaging of muscle-invasive bladder cancer (MBC) is restricted to its locoregional and distant metastases, since most radiopharmaceuticals have a urinary excretion that limits the visualization of the primary tumor. <sup>64</sup>CuCl<sub>2</sub> <sub>,</sub> a positron-emitting radiotracer with nearly exclusive biliary elimination, could be well suited to exploring urinary tract neoplasms. In this study, we evaluated the feasibility of <sup>64</sup>CuCl<sub>2</sub>-based staging of patients with MBC; furthermore, we compared the diagnostic capability of this method with those of the current gold standards, that is, contrast-enhanced CT (ceCT) and <sup>18</sup>F-FDG PET/CT. <b>Methods:</b> We prospectively enrolled patients referred to our institution for pathology-confirmed MBC staging/restaging between September 2021 and January 2023. All patients underwent ceCT, <sup>18</sup>F-FDG, and <sup>64</sup>CuCl<sub>2</sub> PET/CT within 2 wk. Patient-based analysis and lesion-based analysis were performed for all of the potentially affected districts (overall, bladder wall, lymph nodes, skeleton, liver, lung, and pelvic soft tissue). <b>Results:</b> Forty-two patients (9 women) were enrolled. Thirty-six (86%) had evidence of disease, with a total of 353 disease sites. On patient-based analysis, ceCT and <sup>64</sup>CuCl<sub>2</sub> PET/CT showed higher sensitivity than <sup>18</sup>F-FDG PET/CT in detecting the primary tumor (<i>P</i> < 0.001); moreover, <sup>64</sup>CuCl<sub>2</sub> PET/CT was slightly more sensitive than <sup>18</sup>F-FDG PET/CT in disclosing soft-tissue lesions (<i>P</i> < 0.05). Both PET methods were more specific and accurate than ceCT in classifying nodal lesions (<i>P</i> < 0.05). On lesion-based analysis, <sup>64</sup>CuCl<sub>2</sub> PET/CT outperformed <sup>18</sup>F-FDG PET/CT and ceCT in detecting disease localizations overall (<i>P</i> < 0.001), in the lymph nodes (<i>P</i> < 0.01), in the skeleton (<i>P</i> < 0.001), and in the soft tissue (<i>P</i> < 0.05). <b>Conclusion:</b> <sup>64</sup>CuCl<sub>2</sub> PET/CT appears to be a sensitive modality for staging/restaging of MBC and might represent a "one-stop shop" diagnostic method in these scenarios.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Fluorodeoxyglucose F18
- Urinary Bladder Neoplasms
- Neoplasm Staging
- Neoplasm Invasiveness